Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis.

ABSTRACT:

Background

Checkpoint inhibitor-related pneumonitis (CIP) is a lethal immune-related adverse event. However, the development process of CIP, which may provide insight into more effective management, has not been extensively examined.

Methods

We conducted a multicenter retrospective analysis of 56 patients who developed CIP. Clinical characteristics, radiological features, histologic features, and laboratory tests were analyzed. After a comprehensive analysis, we proposed acute, subacute, and chronic phases of CIP and summarized each phase's characteristics.

Results

There were 51 patients in the acute phase, 22 in the subacute phase, and 11 in the chronic phase. The median interval time from the beginning of CIP to the different phases was calculated (acute phase: ≤4.9

SUBMITTER: Zhou C 

PROVIDER: S-EPMC9364904 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature